Objective: The ideal medication for the treatment of acid-related diseases, e.g., peptic ulcers, stressrelated gastric bleeding, functional dyspepsia, and gastroesophageal reflux disease, should have a rapid onset of action to promote hemostasis and relieve the symptoms. The aim of our study was to investigate the inhibitory effects on gastric acid secretion of a single oral administration of a proton pump inhibitor, omeprazole 20 mg, and an H 2 -receptor antagonist, roxatidine 75 mg. Methods: Ten Helicobacter pylori-negative male subjects participated in this randomized, two-way crossover study. Intragastric pH was monitored continuously for 6 h after single oral administration of omeprazole 20 mg and roxatidine 75 mg. Each administration was separated by a 7-d washout period. Results: During the 6-h study period, the average pH after administration of roxatidine was higher than that after administration of omeprazole (median: 4.45 vs. 2.65; P=0.0367). Also during the 6-h study period, a longer duration of maintenance at pH above 2, 5, and 6 was observed after administration of roxatidine 75 mg than after administration of omeprazole 20 mg (median: 90.6% vs. 55.2%, P=0.0284; 43.7% vs. 10.6%, P=0.0125; 40.3% vs. 3.3%, P=0.0125; respectively). Conclusions: In Helicobacter pylori-negative healthy male subjects, oral administration of roxatidine 75 mg increased the intragastric pH more rapidly than that of omeprazole 20 mg.
Introduction
The ideal medication for acid-related diseases, especially peptic ulcer, stress-related gastric bleeding, functional dyspepsia, and gastroesophageal reflux disease (GERD), should have a rapid onset of action in decreasing the intragastric acidity, because in-vitro studies have shown that blood coagulation and platelet aggregation are abolished at a pH less than 5.4 (Green et al., 1978) . Multiple agents, including antacids, H 2 -receptor antagonists, and proton pump inhibitors, are currently available. Proton pump inhibitors are the most potent inhibitors of gastric acid secretion when used regularly (Burget et al., 1990 ). However, a few studies have compared the time course of the effects of single oral dose administration of proton pump inhibitors and H 2 -receptor antagonists. We designed this crossover study to compare the acute effects of single oral administration of omeprazole 20 mg and roxatidine 75 mg on intragastric pH.
Materials and methods

Subjects
This was a randomized, two-way crossover study of 10 healthy male volunteers with a mean age of 29.1 years (range: 23-44 years), who were not using acid-suppressive medications including antacids, H 2 -receptor antagonists, and/or proton pump inhibitors. All subjects were negative for antiHelicobacter pylori immunoglobulin G (IgG) antibodies (SRL Inc., Tokyo, Japan).
Study protocol and pH-metry
In this crossover study, all subjects received a single oral dose of omeprazole 20 mg (AstraZeneca Pharmaceutical Co. Ltd., Osaka, Japan) and a single oral dose of roxatidine 75 mg (ASKA Pharmaceutical Co. Ltd., Tokyo, Japan) in a random sequence. The drugs were administered with a washout period of at least 7 d between the two administrations. The subjects were requested to fast overnight (at least 8 h) before the treatment and also during a period of 6 h after the drug administration, and both drugs were given in the morning.
The pH electrode was inserted transnasally under local anesthesia and located in the body of the stomach. The gastric pH was measured at 10-s intervals with a portable pH meter equipped with an antimony pH electrode (Chemical Instrument Co. Ltd., Tokyo, Japan). The pH electrode was calibrated before each recording using standard buffers of pH 4.01 and 6.86. The pH data were analyzed using established software (Chemical Instrument Co. Ltd., Tokyo, Japan). The average pH and the percentage duration of the 6-h monitoring period over which the intragastric pH remained above 1.0, 2.0, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0, and 8.0 after each drug administration were also measured (Iida et al., 2009 ).
CYP2C19 genotyping
DNA samples were obtained from white blood cells separated from whole blood samples obtained from the 10 subjects. The S-mephenytoin 4′-hydroxylase (CYP2C19) genotype was determined by polymerase chain reaction (PCR)-restriction fragment length polymorphism analysis (Kubota et al., 1996) . There are two point mutations of CYP2C19: the wild-type allele has G at position 636 in exon 4 and G at position 689 in exon 5; one of the mutated alleles (m1 allele) has A at position 689 in exon 5, and the other mutated allele (m2 allele) has A at position 636 in exon 4 (de Morais et al., 1994a; 1994b) . The CYP2C19 genotyping was performed by SRL Inc., Tokyo, Japan (Abe et al., 2004) .
Statistics
Statistical evaluation was carried out using the Wilcoxon signed-rank test. The level of significance was set at P<0.05. The statistical analyses were performed using the Stat View program (SAS Institute, Cary, NC, USA).
Ethics
The study was conducted in accordance with the Declaration of Helsinki, and with the approval of the Ethics Committee of Yokohama City University School of Medicine, Japan.
Results
Adverse events
All subjects completed the study. No adverse events were recorded during the study.
Average pH
The average pH during the 6-h study period after administration of roxatidine 75 mg was higher than that after administration of omeprazole 20 mg (median: 4.43 vs. 2.65, respectively; P=0.0367) (Fig. 1) .
The average pH was significantly higher after administration of roxatidine 75 mg as compared with that after administration of omeprazole 20 mg, in all the time periods measured: 0-1 h (median: 2.20 vs. (Fig. 2) .
Holding time of various pH levels for over 4 h
During the 6-h study period, a longer duration of maintenance at pH above 2, 5 and 6 was observed after administration of roxatidine 75 mg as compared with that after administration of omeprazole 20 mg (median: 90.6% vs. 55.2%, P=0.0284; 43.7% vs. 10.6%, P=0.0125; 40.3% vs. 3.3%, P=0.0125; respectively) (Fig. 3) .
CYP2C19 genotype
The results of CYP2C19 genotyping revealed nine subjects to be extensive metabolizers, including four homozygous extensive metabolizers with two wild-type alleles, and five heterozygous extensive metabolizers with one wild-type allele and one mutated allele; the remaining one subject was determined to be a poor metabolizer, with two mutated alleles.
After administration of omeprazole and roxatidine, the average pH values during the 6-h study period were 2.8 and 3.9 in the homozygous extensive metabolizers, 2.4 and 5.0 in the heterozygous extensive metabolizers, and 4.2 and 4.5 in the poor metabolizers (median values).
Discussion
In this study, we examined the change of intragastric pH after a single oral administration of omeprazole 20 mg and roxatidine 75 mg, in the early post-administration phase, in Helicobacter pylorinegative subjects. We observed that roxatidine had a significantly faster onset of action and produced a stronger inhibition of intragastric acid secretion than omeprazole. These study results support the previous reports (Hurlimann et al., 1994; Chassany et al., 1996; Arnestad et al., 1997; Hedenstrom et al., 1997; Khoury et al., 1999; Abe et al., 2004; Inamori et al., 2005; Iida et al., 2009 ) that H 2 -receptor antagonists Fig. 1 Average pH during the first 6 h Average pH during the first 6 h after administration of roxatidine was higher than that after administration of omeprazole.
* P=0.0367 by the Wilcoxon signed-rank test increase intragastric pH more rapidly than proton pump inhibitors.
We selected omeprazole for study, among various currently available proton pump inhibitors, for several reasons. First, omeprazole has been used for over 20 years and is one of the most used drugs in Japan. Second, omeprazole 20 mg has been indicated for both initial therapy and maintenance therapy. Roxatidine was discovered as an H 2 -receptor antagonist in Japan (Tarutani et al., 1985) and is used to treat peptic ulcer, functional dyspepsia, and gastroesophageal reflux disease. Roxatidine blocks gastric acid secretion and it has been shown to be approximately six-fold more potent than cimetidine in the inhibition of gastric acid secretion (Tarutani et al., 1985) . In addition, roxatidine has been demonstrated to accelerate mucus secretion in animals and human (Ichikawa et al., 1999; Saito et al., 2000) .
Omeprazole is inactivated by CYP2C19, while roxatidine is eliminated via the urine. Significant differences of acid secretion have been shown between extensive and poor metabolizers of CYP2C19 (Andersson, 1996; Williams et al., 1998; Furuta et al., 1999; Shirai et al., 2001; Saitoh et al., 2002) . The frequency of the poor metabolizer phenotype of CYP2C19 shows variations: only 2% to 6% of Whites, as compared with 19% to 23% of Japanese (Wedlund et al., 1984; Kubota et al., 1996; Ishizaki and Horai, 1999) . One of the 10 subjects (10%) in our study was identified to be a poor metabolizer.
The present results are also supported by the results of an in vitro study. In an autoradiographic study, Nakamura et al. (1995) reported that H 2 -receptor antagonists accumulated equally on the parietal cells, while proton pump inhibitors accumulated only on young activated parietal cells. Nakamura et al. (1995) hypothesized that, because other proton pumps are quickly activated, the anti-secretory effect of proton pump inhibitors was not faster than that of H 2 -receptor antagonists in the early phase postadministration.
Prophylactic treatment with oral H 2 -receptor antagonists has been shown to reduce the bleeding rate (Moore, 1991; Smythe and Zarowitz, 1994) , confirming the importance of raising the intragastric pH to prevent or treat stress ulcers. However, the intragastric pH necessary for protection against stress-related mucosal damage is not well established and, therefore, the optimal pH for the prevention of stress ulcers and bleeding is a subject for debate. Maintenance of the intragastric pH above 3.5 to 4.0 is thought to be necessary for preventing stress ulcers (Stothert et al., 1980; Frank et al., 1986; Watanabe et al., 1990) , while an intragastric pH of over 6 is necessary for the treatment of existing stress ulcers (Fullarton et al., 1991) . Our results show that a single oral administration of roxatidine produces a more rapid antisecretory effect as compared with omeprazole, and roxatidine may be suitable for initial therapy to promote hemostasis and for on-demand therapy in outpatients to relieve symptoms. On the other hand, omeprazole has more potent anti-secretory activity and is more effective than H 2 -receptor antagonists in healing ulcers. This finding may be explained by studies that have shown that the anti-secretory activity of proton pump inhibitors increases progressively after repeated oral and intravenous administration, with a steady state achieved after about 5 d (Howden et al., 1984; Jansen et al., 1988) . In one study, a daily intravenous injection dose of proton pump inhibitors was not sufficient to maintain an intragastric pH (>4) during the first day of treatment (Jansen et al., 1988) . However, after 5-7 d treatment, oral proton pump inhibitors were more effective than H 2 -receptor antagonists in normal subjects, patients with duodenal ulcer, and those with GERD (Ohara et al., 1988; Ducrotté et al., 1994) .
In conclusion, roxatidine 75 mg increases intragastric pH more rapidly than omeprazole 20 mg in Helicobacter pylori-negative subjects. This study shows that roxatidine 75 mg is more suitable for on-demand therapy to relieve symptoms than omeprazole 20 mg, when given as a single oral dose.
